132 related articles for article (PubMed ID: 33795611)
1. Determination of tumour dose response threshold and implication on survival in patients with HCC treated with Y90 radiation segmentectomy: a simple semi-quantitative analysis.
Cheng B; Sethi I; Villalobos A; Wagstaff W; Schuster DM; Bercu Z; Brandon D; Kokabi N
Nucl Med Commun; 2021 Aug; 42(8):892-898. PubMed ID: 33795611
[TBL] [Abstract][Full Text] [Related]
2. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.
Cheng B; Villalobos A; Sethi I; Wagstaff W; Galt J; Brandon D; Schuster DM; Bercu Z; Majdalany B; Kokabi N
Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1194-1203. PubMed ID: 33890170
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90 dosimetry and implications on tumour response and survival after radioembolisation of chemo-refractory hepatic metastases from breast cancer.
Cheng B; Sethi I; Davisson N; Brandon D; Barron B; Galt J; Bercu Z; Schuster DM; Kokabi N
Nucl Med Commun; 2021 Apr; 42(4):402-409. PubMed ID: 33306630
[TBL] [Abstract][Full Text] [Related]
4. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.
Kokabi N; Arndt-Webster L; Chen B; Brandon D; Sethi I; Davarpanahfakhr A; Galt J; Elsayed M; Bercu Z; Cristescu M; Kappadath SC; Schuster DM
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1743-1752. PubMed ID: 36650357
[TBL] [Abstract][Full Text] [Related]
5. Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Comparative Study of the Effectiveness, Safety, and Dosimetry of Glass-Based versus Resin-Based Microspheres.
Villalobos A; Arndt L; Cheng B; Dabbous H; Loya M; Majdalany B; Bercu Z; Kokabi N
J Vasc Interv Radiol; 2023 Jul; 34(7):1226-1234. PubMed ID: 36958669
[TBL] [Abstract][Full Text] [Related]
6. Tumor-to-Normal Ratio Relationship between Planning Technetium-99 Macroaggregated Albumin and Posttherapy Yttrium-90 Bremsstrahlung SPECT/CT.
Villalobos A; Cheng B; Wagstaff W; Sethi I; Bercu Z; Schuster DM; Brandon DC; Galt J; Kokabi N
J Vasc Interv Radiol; 2021 May; 32(5):752-760. PubMed ID: 33642158
[TBL] [Abstract][Full Text] [Related]
7. Role of Resin Microsphere Y90 Dosimetry in Predicting Objective Tumor Response, Survival and Treatment Related Toxicity in Surgically Unresectable Colorectal Liver Metastasis: A Retrospective Single Institution Study.
Sankhla T; Cheng B; Nezami N; Xing M; Sethi I; Bercu Z; Brandon D; Majdalany B; Schuster DM; Kokabi N
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638392
[TBL] [Abstract][Full Text] [Related]
8. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
[TBL] [Abstract][Full Text] [Related]
9. For Hepatocellular Carcinoma Treated with Yttrium-90 Microspheres, Dose Volumetrics on Post-Treatment Bremsstrahlung SPECT/CT Predict Clinical Outcomes.
Taswell CS; Studenski M; Pennix T; Stover B; Georgiou M; Venkat S; Jones P; Zikria J; Thornton L; Yechieli R; Mohan P; Portelance L; Spieler B
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765603
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Non-tumoral Liver Dose with Treatment-Related Adverse Events in Patients with Hepatocellular Carcinoma Treated with Glass-Based Yttrium-90 Radioembolization.
Webster LA; Villalobos A; Cheng B; Xing M; Majdalany BS; Bercu ZL; Cristescu MM; Brandon D; Schuster D; Baum Y; Loya MF; Kokabi N
Cardiovasc Intervent Radiol; 2023 Jan; 46(1):60-68. PubMed ID: 36450996
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Medium-Term Efficacy of Y90 Radiation Segmentectomy vs Percutaneous Microwave Ablation in Patients with Solitary Surgically Unresectable < 4 cm Hepatocellular Carcinoma: A Propensity Score Matched Study.
Arndt L; Villalobos A; Wagstaff W; Cheng B; Xing M; Ermentrout RM; Bercu Z; Cristescu M; Shah A; Wedd J; Majdalany BS; Magliocca JF; Sellers MT; Kokabi N
Cardiovasc Intervent Radiol; 2021 Mar; 44(3):401-413. PubMed ID: 33230652
[TBL] [Abstract][Full Text] [Related]
12. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
13. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort.
Das A; Riaz A; Gabr A; Ali R; Mora R; Al Asadi A; Mouli S; Lewandowski RJ; Salem R
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):807-815. PubMed ID: 31502015
[TBL] [Abstract][Full Text] [Related]
15. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
[TBL] [Abstract][Full Text] [Related]
16. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
[TBL] [Abstract][Full Text] [Related]
17. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular Carcinoma Tumor Dose Response After
Kappadath SC; Mikell J; Balagopal A; Baladandayuthapani V; Kaseb A; Mahvash A
Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):451-461. PubMed ID: 30191875
[TBL] [Abstract][Full Text] [Related]
19. Using Deep Learning to Predict Treatment Response in Patients with Hepatocellular Carcinoma Treated with Y90 Radiation Segmentectomy.
Wagstaff WV; Villalobos A; Gichoya J; Kokabi N
J Digit Imaging; 2023 Jun; 36(3):1180-1188. PubMed ID: 36629989
[TBL] [Abstract][Full Text] [Related]
20. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with
Garin E; Rolland Y; Pracht M; Le Sourd S; Laffont S; Mesbah H; Haumont LA; Lenoir L; Rohou T; Brun V; Edeline J
Liver Int; 2017 Jan; 37(1):101-110. PubMed ID: 27514012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
